Dashboard
Weak Long Term Fundamental Strength with a -2.97% CAGR growth in Net Sales over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.35
- The company has been able to generate a Return on Equity (avg) of 5.18% signifying low profitability per unit of shareholders funds
Flat results in Sep 26
With ROE of 4.9, it has a Expensive valuation with a 1.6 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
INR 17 Cr (Micro Cap)
33.00
40
0.00%
-0.81
4.94%
1.73
Total Returns (Price + Dividend) 
Colinz Labs for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Colinz Laboratories Ltd: Valuation Shift Signals Renewed Price Attractiveness
Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting evolving investor perceptions amid a mixed performance backdrop. This recalibration comes as the company’s price-to-earnings (P/E) ratio moderates to 35.05, aligning more closely with sector peers, while price-to-book value (P/BV) stands at 1.73, signalling a more balanced price attractiveness compared to historical levels.
Read More
Colinz Laboratories Ltd Valuation Shifts Signal Growing Price Pressure
Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift notably towards an expensive zone, reflecting a significant change in market perception. Despite this, the company’s stock has delivered robust returns over multiple time frames, outperforming the Sensex by a wide margin.
Read More
Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness
Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its robust returns over multiple time horizons, invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
31-Oct-2026 | Source : BSEDear sir
Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.
29-Oct-2026 | Source : BSEThe Attached Results for Quarter ended on 30-9-2026 was approved in Bopard Meeting held on 29-10-2026 as required under Regulation 30 and 33 and our Auditors have issued Limited Review Report on the same.
Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.
29-Oct-2026 | Source : BSEWe would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 29th October 2026 has inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September 2026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Vijaya Mani (34.56%)
Padam Dugar (12.54%)
46.9%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 25.00% vs -29.14% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -94.58% vs 1,311.76% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -18.28% vs -2.17% in Sep 2024
Growth in half year ended Sep 2025 is -10.34% vs 20.83% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -13.78% vs -5.93% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 0.00% vs -2.86% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -5.97% vs -7.11% in Mar 2025
YoY Growth in year ended Mar 2026 is 2.00% vs 2.04% in Mar 2025